Chronic Obstructive Pulmonary Disease: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Chronic Obstructive Pulmonary Disease: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018

  • 230 Pages | 15-Sep-18 | Format:PDF | Last Updated: 15-Sep-18
  • GervanoRA’s pipeline analysis and opportunity assessment report “Chronic Obstructive Pulmonary Disease: Opportunity Assessments, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Chronic Obstructive Pulmonary Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Obstructive Pulmonary Disease industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline Molecules
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    2.1. REPORTS MAJOR FINDINGS
    2.2. KEY PIPELINE EVENTS 2018 TO 2029
    3 DISEASE OVERVIEW
    3.1. DEFINITION AND SYMPTOMS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHMS AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    4 MARKET OVERVIEW
    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    4.1.1. COLLABORATION AGREEMENTS
    4.1.2. LICENSING AGREEMENTS
    4.1.3. ACQUISITIONS
    4.1.4. COMMERCIALIZATION AGREEMENTS
    4.1.5. OTHER DEALS IN COPD
    4.2. NEW DRUG APPROVALS (USFDA) SINCE 2010
    4.3. NEW DRUG APPROVALS (EMA) SINCE 2010
    4.4. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5 PIPELINE ANALYSIS
    5.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    5.1.2. PHASE III MOLECULES
    5.1.3. PHASE II MOLECULES
    5.1.4. PHASE I MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. PIPELINE MOLECULES BY COMPANIES, UNIVERSITIES AND INSTITUTES
    5.6.1. COMPANIES
    5.6.2. UNIVERSITIES AND INSTITUTES
    6 ESTIMATED DRUG APPROVAL TIMELINES
    6.1. METHODOLOGY
    6.2. UNITED STATES (FDA) AND EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
    7 COPD CLINICAL TRIAL SUMMARY
    7.1. COPD PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    7.1.1. KEY PHASE III RESULTS
    7.1.2. KEY PHASE II RESULTS
    7.2. ONGOING CLINICAL TRIALS SUMMARY
    7.3. PLANNED CLINICAL TRIALS SUMMARY
    7.4. RECENTLY COMPLETED CLINICAL TRIAL RESULTS
    8 WITHDRAWN & DISCONTINUED PROJECTS
    8.1. WITHDRAWN PROJECTS
    8.2. TERMINATED PROJECTS
    9 CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    9.1. COMPANIES
    9.1.1. ESTABLISHED COMPANIES WITH PRODUCT PROFILES AND MILESTONES
    9.1.2. ESTABLISHED COMPANIES PROFILES AND SWOT
    9.1.3. EMERGING COMPANIES
    9.1.4. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    9.2. UNIVERSITIES AND INSTITUES
    10 ABBREVIATIONS

    LIST OF TABLES

    TABLE 1: AIRFLOW LIMITATION IN PATIENTS WITH FEV1/FVC < 70%
    TABLE 2: GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD)
    TABLE 3: DIFFERENTIAL DIAGNOSIS BETWEEN COPD AND ASTHMA
    TABLE 4: COPD COLLABORATION AGREEMENTS (2001-2018)
    TABLE 5: COPD LICENSING AGREEMENTS (2005-2017)
    TABLE 6: MAJOR COPD ACQUISITIONS
    TABLE 7: MAJOR COPD COMMERCIALISATION AGREEMENTS
    TABLE 8: OTHER COPD DEALS
    TABLE 9: US FDA APPROVED DRUGS FOR COPD
    TABLE 10: EMA APPROVED DRUGS FOR COPD
    TABLE 11: TRELEGY ELLIPTA GRANTED PATENTS, GLAXOSMITHKLINE
    TABLE 12: LONHALA MAGNAIR GRANTED PATENTS AND APPLICATIONS, SUNOVION PHARMACEUTICALS
    TABLE 13: STIOLTO RESPIMAT US GRANTED PATENTS, BOEHRINGER INGELHEIM
    TABLE 14: UTIBRON NEOHALER US GRANTED PATENTS, SUNOVION PHARMACEUTICALS
    TABLE 15: ANORO ELLIPTA US GRANTED PATENTS, GLAXOSMITHKLINE
    TABLE 16: RAYOS US GRANTED PATENTS, HORIZON PHARMA
    TABLE 17: TUDORZA PRESSAIR PATENTS, ASTRAZENECA
    TABLE 18: TUDORZA PRESSAIR US GRANTED PATENTS, ASTRAZENECA
    TABLE 19: DALIRESP PATENT EXPIRIES
    TABLE 20: RIARIFY US GRANTED PATENTS, CHIESI FARMACEUTICI
    TABLE 21: AERIVIO SPIROMAX US GRANTED PATENTS, TEVA B.V.
    TABLE 22: SEEBRI BREEZHALER US GRANTED PATENTS
    TABLE 23: DUAKLIR GENUAIR PATENTS
    TABLE 24: PRE-REGISTRATION (FILED) MOLECULES IN THE COPD DRUG PIPELINE
    TABLE 25: COPD DRUG PIPELINE MOLECULES IN PHASE III STAGE OF DEVLOPMENT
    TABLE 26: COPD DRUG PIPELINE MOLECULES IN PHASE II STAGE OF DEVLOPMENT
    TABLE 27: COPD DRUG PIPELINE MOLECULES IN PHASE I STAGE OF DEVELOPMENT
    TABLE 28: COPD DRUG PIPELINE MOLECULES IN PRECLINICAL STAGE OF DEVELOPMENT
    TABLE 29: COPD DRUG PIPELINE MOLECULES IN EARLY R&D STAGE OF DEVLOPMENT
    TABLE 30: COPD DRUG PIPELINE BY INHALATION AS ROUTE OF ADMINISTRATION
    TABLE 31: COPD DRUG PIPELINE BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 32: COPD DRUG PIPELINE BY INJECTABLE AS ROUTE OF ADMINISTRATION
    TABLE 33: COPD DRUG PIPELINE, BRONCHODILATORS
    TABLE 34: COPD DRUG PIPELINE, CYTOKINE INHIBITORS
    TABLE 35: COPD DRUG PIPELINE, MUSCARINIC ANTAGONISTS
    TABLE 36: COPD DRUG PIPELINE, MONOCLONAL ANTIBODIES
    TABLE 37: COPD DRUG PIPELINE- LABA AND LAMA, MECHANISM OF ACTION
    TABLE 38: COPD DRUG PIPELINE- MABA, MECHANISM OF ACTION
    TABLE 39: COPD DRUG PIPELINE- INTERLEUKIN INHIBITION, MECHANISM OF ACTION
    TABLE 40: COPD DRUG PUIPELINE- OTHER MECHANISMS, MECHANISM OF ACTION
    TABLE 41: ESTIMATED DRUG APPROVAL TIMELINE FOR COPD DRUGS IN THE PIPELINE
    TABLE 42: PRIMARY ENDPOINT RESULTS ASSESSED BY FEV1
    TABLE 43: TERMINATED COPD PROJECTS
    TABLE 44: COMPANY SNAPSHOT, GSK
    TABLE 45: MAJOR PRODUCTS, GSK
    TABLE 46: COMPANY SNAPSHOT, SUNOVION PHARMACEUTICALS
    TABLE 47: COMPANY SNAPSHOT, HORIZON PHARMA
    TABLE 48 : TOTAL NET SALES, 2017 V/S 2016 V/S 2015, HORIZON PHARMA
    TABLE 49: COMPANY SNAPSHOT, ASTRAZENECA
    TABLE 50: COMPANY SNAPSHOT, NOVARTIS
    TABLE 51: MAJOR PRODUCTS, NOVARTIS
    TABLE 52: COMPANY SNAPSHOT, BOEHRINGER INGELHEIM
    TABLE 53: COMPANY SNAPSHOT, CHIESI FARMACEUTICI S.P.A.
    TABLE 54: COMPANY SNAPSHOT, TEVA PHARMACEUTICAL LTD.
    TABLE 55: LIST OF UNIVERSITIES, COPD
    TABLE 56: LIST OF INSTITUTES, COPD

    LIST OF FIGURES
    FIGURE 1: COPD DEAL MAKING SCENARIO (2001-2018)
    FIGURE 2: COPD DRUG PIPELINE MOLECULES DEVELOPMENT BY COMPANIES, UNIVERSITIES AND INSTITUTES
    FIGURE 3: COPD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES
    FIGURE 4: COPD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 5: COPD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 6: COPD DRUG PIPELINE PHASES BY ROUTE OF ADMINISTRATION
    FIGURE 7: COPD DRUG PIPELINE – UNIVERSITIES AND INSTITUTES

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)